{"id":"ara-290","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL3545305","moleculeType":"Protein","molecularWeight":"1257.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking glucagon receptors, ARA 290 aims to reduce glucose production in the liver, thereby lowering blood glucose levels. This mechanism is particularly relevant for the treatment of type 2 diabetes. ARA 290's glucagon receptor antagonism is thought to be a key factor in its therapeutic effects.","oneSentence":"ARA 290 is a peptide that acts as a glucagon receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:58.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06483620","phase":"","title":"Cross-cultural Adaptation and Validity of the Arabic-translated NEUROPATHY-SPECIFIC QUALITY OF LIFE Questionnaire","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-02-13","conditions":"Diabetic Neuropathies, Diabetic Peripheral Neuropathy","enrollment":290},{"nctId":"NCT06626971","phase":"PHASE2","title":"The Use of ARA290 for the Treatment of Diabetic Macular Oedema","status":"TERMINATED","sponsor":"Belfast Health and Social Care Trust","startDate":"2016-04","conditions":"Diabetic Macular Oedema","enrollment":9},{"nctId":"NCT02039687","phase":"PHASE2","title":"Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis","status":"COMPLETED","sponsor":"Araim Pharmaceuticals, Inc.","startDate":"2014-01","conditions":"Neuropathy of Sarcoidosis","enrollment":64},{"nctId":"NCT01933529","phase":"PHASE2","title":"ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)","status":"UNKNOWN","sponsor":"Claes-Göran Östenson","startDate":"2013-10","conditions":"Diabetes Type 2, Impaired Glucose Tolerance, Impaired Fasting Glucose","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pHSBP, Cibinetide"],"phase":"phase_2","status":"active","brandName":"ARA 290","genericName":"ARA 290","companyName":"Claes-Göran Östenson","companyId":"claes-g-ran-stenson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARA 290 is a peptide that acts as a glucagon receptor antagonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}